IRLAB Therapeutics
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
Attachments
Board member leaves IRLAB for another assignment
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/680352/Board-Member-Leaves-IRLAB-for-Another-Assignment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Ushers in Era of Governed and Trustworthy AI Analytics3.12.2025 11:00:00 CET | Press release
New Intelligence Layer allows enterprises to ground AI in governed data, ensuring precision, explainability, and confidence in every decision. SAN FRANCISCO, CA / ACCESS Newswire / December 3, 2025 / GoodData, leader in AI analytics and data intelligence, today announced the launch of its Intelligence Layer, a suite of governed, context-aware AI capabilities that bridge the gap between raw data and trustworthy, action-ready intelligence. Built for organizations operating across complex data environments, whether on-premises or across cloud services, the Intelligence Layer ensures that AI is grounded in a company's own rules, logic, and semantic definitions. Roman Stanek, CEO of GoodData, says: "Most companies don't need more dashboards; they need clarity. They need to know their data is right, easy to understand, and ready to use. That's exactly what the Intelligence Layer is built for." The Intelligence Layer embeds governance and business context directly into the analytical process,
Caldwell Expands Global Financial Services and Real Estate Capabilities with Addition of Ben Sturnham as Partner3.12.2025 11:00:00 CET | Press release
LONDON, UK AND TORONTO, ON / ACCESS Newswire / December 3, 2025 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Ben Sturnham as a Partner in the firm's Financial Services and Real Estate practices. Based in London, Sturnham advises clients on board and C-suite recruitment across the full breadth of the real estate, financial services, and real estate finance sectors in the UK, Europe, and the Middle East. With more than two decades of global experience in executive search, leadership assessment, and organizational development, Sturnham is known for helping investors, lenders, and operators build high-performing leadership teams. "Ben is a deeply respected search professional whose insight, credibility, and sector knowledge make him an exceptional advisor to clients across the financial services and real estate capital ecosystem," said Glenn Buggy and Paul Heller, global managing partners of Caldwell's Financial Services Practice. "His ap
New GTDC Report Highlights Effective Methods for Building Optimal Channel Strategies2.12.2025 15:00:00 CET | Press release
TAMPA, FL / ACCESS Newswire / December 2, 2025 / The Global Technology Distribution Council (GTDC) has released a groundbreaking new industry study titled "Building the Optimal Distribution Strategy." This comprehensive guide provides insights and valuable best practices for evaluating market and channel coverage needs and determining which types of distributors provide the best fit for technology suppliers. Former global channel chief and partner route to market specialist Donna Grothjan led the development of this member-inspired GTDC project, adding her personal knowledge and experience creating and managing distribution strategies, as well as gathering and sharing insight from respected industry peers and subject matter experts. Distribution remains the most cost-effective route-to-market for technology suppliers. That value is rising rapidly in the cloud era as emerging and legacy vendors look to scale sales, support and other operations around these virtual offerings without requ
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases2.12.2025 06:00:00 CET | Press release
Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / December 2, 2025 / GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today. SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases. This Phase 1 randomized, d
TheaMou by Theo Announces Global Revival of the Original Olympic Games and Operation PAME BROSTA at Athens Fashion Week26.11.2025 19:00:00 CET | Press release
TheaMou Ignites Athens Fashion Week with a Goddess-Warrior Revival Rooted in Ancient Greece ATHENS, GREECE / ACCESS Newswire / November 26, 2025 / TheaMou by Theo ("My Goddess" in Greek), the creative umbrella uniting MeaDea by Theo, Iellele by Theo, MiDiosa by Theo, and aligned cultural initiatives, presented its Ancient Greek Goddess & Warrior Collection at Athens Fashion Week on November 14th, 2025. Founder, Sam Stathis, used the Athens Fashion Week stage to officially launch operation PAME BROSTA (Moving forward in Greek) and announce the global revival of the ORIGINAL OLYMPIC GAMES.Sam Stathis with Olympic Angels at Athens Fashion Week Sam Stathis with Olympic Angels and TheaMou by MeaDea models at Athens Fashion Week Three Olympic Angels by Theo, each a crowned national beauty queen (Miss Greece-Star Hellas, Stella Mihailidou, Miss Italia, Federica Rizza, and Miss Netherlands, Elize DeJong), opened the runway show, symbolizing the revival of the True Flame of Greece through divin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom